Trials / Completed
CompletedNCT01749878
Study to Assess the Safety and Tolerability of Single Doses of REGN1500
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Phase 1, first-in-human, randomized, ascending single-dose, placebo-controlled, double-blind study of the safety, tolerability, and bioeffect of REGN1500
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1500 | |
| DRUG | placebo |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2012-12-17
- Last updated
- 2016-05-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01749878. Inclusion in this directory is not an endorsement.